Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded at StockNews.com

StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a buy rating in a research note issued to investors on Tuesday.

Separately, HC Wainwright restated a neutral rating on shares of Oramed Pharmaceuticals in a research note on Monday, May 20th.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ:ORMP opened at $2.40 on Tuesday. Oramed Pharmaceuticals has a 52 week low of $1.67 and a 52 week high of $3.67. The company’s fifty day moving average is $2.45 and its 200-day moving average is $2.57. The company has a market capitalization of $97.51 million, a PE ratio of 9.23 and a beta of 1.79.

Institutional Trading of Oramed Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its stake in shares of Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 10,774 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Oramed Pharmaceuticals in the 2nd quarter valued at about $40,000. Assenagon Asset Management S.A. bought a new stake in shares of Oramed Pharmaceuticals in the 1st quarter valued at about $54,000. Virtu Financial LLC bought a new stake in shares of Oramed Pharmaceuticals in the 1st quarter valued at about $68,000. Finally, Renaissance Technologies LLC increased its stake in shares of Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after acquiring an additional 108,700 shares during the last quarter. 12.73% of the stock is owned by institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.